Your browser doesn't support javascript.
loading
In vivo dosimetric impact of breast tissue expanders on post-mastectomy radiotherapy.
Gee, Harriet E; Bignell, Fiona; Odgers, David; Gill, Simran; Martin, Darren; Toohey, Joanne; Carroll, Susan.
Afiliação
  • Gee HE; Department of Radiation Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
  • Bignell F; Central Clinical School, School of Medicine, University of Sydney, Sydney, New South Wales, Australia.
  • Odgers D; Radiation Oncology Department, Auckland City Hospital, Auckland, New Zealand.
  • Gill S; Department of Radiation Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
  • Martin D; Department of Radiation Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
  • Toohey J; Department of Radiation Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
  • Carroll S; Department of Radiation Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
J Med Imaging Radiat Oncol ; 60(1): 138-45, 2016 Feb.
Article em En | MEDLINE | ID: mdl-26503758
ABSTRACT

INTRODUCTION:

Temporary tissue expanders with metallic ports for gradual saline injection are increasingly employed to facilitate breast reconstruction after post-mastectomy radiotherapy (PMRT). Treatment beams therefore pass through a high-density rare-earth magnet. Measurements ex vivo suggest attenuation of dose to the skin and chest wall at clinical risk of relapse. The purpose of the study was to quantify the resulting dose reduction in vivo, compared with treatment planning system (TPS).

METHODS:

Sixteen patients receiving PMRT had in vivo dosimetry prospectively performed with ethics board approval. Port was located within the expanded chest wall using the planning CT scan. Strips of radiochromic film were laid on the skin surface underneath the bolus. To aid interpretation, ex vivo measurements were also performed, including comparison with TPS predictions.

RESULTS:

An average 7% reduction in dose to skin surface was measured in 15 of 16 patients. This was reproducibly located in the 'shadow' of the magnet, corresponding to each of the paths of the medial and lateral tangents. The average area was 1.07 cm(2) (range 0.39 cm(2) to 2.36 cm(2)). Ex vivo measurements confirmed attenuation of the beam in the shadow of the port. The surface area of the 'cold-spot' varied with angle of the beam relative to the metallic port. Dose attenuation in vivo differed from that predicted by the TPS.

CONCLUSION:

Dose is attenuated in the 'shadow' of the tissue expander port in patients receiving PMRT. This is likely to be clinically insignificant for most, but centres should undertake appropriate measurements before utilising TPS predictions.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Planejamento da Radioterapia Assistida por Computador / Neoplasias da Mama / Radioterapia Adjuvante / Implantes de Mama / Exposição à Radiação / Mastectomia Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adult / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Planejamento da Radioterapia Assistida por Computador / Neoplasias da Mama / Radioterapia Adjuvante / Implantes de Mama / Exposição à Radiação / Mastectomia Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adult / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article